Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
Use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis: A systematic literature review.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vij Oliver, Krishnakumar Mathangi, Elwell Helen, Dey Mrinalini, Kouranloo Koushan
Аннотация
BACKGROUND AND AIM: Symptoms, severity and response to treatment of sarcoidosis can follow a heterogenous pattern, presenting a clinical challenge. Use of Fludeoxyglucose F18 Positron Emission Tomography (18F-FDG PET) in disease monitoring remains uncertain. We undertook a systematic literature review on the use of 18F-FDG PET in assessing response to treatment in adults with pulmonary sarcoidosis.
METHODS: Articles discussing 18F-FDG PET use in response to treatment in pulmonary sarcoidosis published until January 2024 were included. All article types were eligible except opinion pieces, case reports, case series of ≤10 patients and reviews.
RESULTS: Time between baseline 18F-FDG PET and follow-up scan ranged from 2 to 6 months. Compared to clinical response, sensitivity of 18F-FDG PET in determining response to treatment ranged from 56% to 100%, with mean sensitivity of 75.3% (SD 16.0).
CONCLUSIONS: 18F-FDG PET could be considered in monitoring response to immunosuppression in patients with pulmonary sarcoidosis.
METHODS: Articles discussing 18F-FDG PET use in response to treatment in pulmonary sarcoidosis published until January 2024 were included. All article types were eligible except opinion pieces, case reports, case series of ≤10 patients and reviews.
RESULTS: Time between baseline 18F-FDG PET and follow-up scan ranged from 2 to 6 months. Compared to clinical response, sensitivity of 18F-FDG PET in determining response to treatment ranged from 56% to 100%, with mean sensitivity of 75.3% (SD 16.0).
CONCLUSIONS: 18F-FDG PET could be considered in monitoring response to immunosuppression in patients with pulmonary sarcoidosis.